We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+10.9%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.81B
AUM Growth
+$244M
Cap. Flow
-$7.27M
Cap. Flow %
-0.19%
Top 10 Hldgs %
49.66%
Holding
160
New
23
Increased
21
Reduced
32
Closed
35

Top Buys

Rank Stock Value
1
VRCA icon
Verrica Pharmaceuticals
VRCA
+$66.8M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$63.1M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$56.2M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$31.2M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$107M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$34.2M
4
ANAB icon
AnaptysBio
ANAB
+$24.7M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.46%
2 Miscellaneous 4.3%
3 Industrials 0.65%
4 Consumer Staples 0.53%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.2B
$463M 12.14%
4,715,250
-46,739
-1% -$4.18M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$313M 8.2%
20,024,424
– –
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
$218M 5.72%
4,828,910
-160,156
-3% -$7.29M
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$31.9B
$182M 4.77%
1,846,911
+566,109
+44% +$56.2M
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$175M 4.6%
3,970,357
– –
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$126M 3.3%
4,313,611
– –
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$108M 2.84%
2,743,647
-183,802
-6% -$5.83M
DOVA
8
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$93.5M 2.45%
3,125,851
+344,874
+12% +$9.39M
IOVA icon
9
Iovance Biotherapeutics
IOVA
$4.24B
$74.9M 1.96%
5,852,202
-310,000
-5% -$4.53M
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$74.1M 1.94%
1,528,205
+11,946
+0.8% +$435K
ASND icon
11
Ascendis Pharma A/S
ASND
$15.8B
$71.4M 1.87%
1,072,647
+90,000
+9% +$5.92M
VRCA icon
12
Verrica Pharmaceuticals
VRCA
$78.7M
$67.3M 1.76%
+341,041
New +$66.8M
RGNX icon
13
Regenxbio
RGNX
$525M
$62.2M 1.63%
867,106
-14,000
-2% -$669K
BPMC
14
DELISTED
Blueprint Medicines
BPMC
$61M 1.6%
961,147
-69,287
-7% -$5.51M
ALBO
15
DELISTED
Albireo Pharma Inc
ALBO
$60.5M 1.59%
1,704,330
– –
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$57.5M 1.51%
463,450
-410,000
-47% -$47.9M
TVTX icon
17
Travere Therapeutics
TVTX
$5.89B
$57.4M 1.5%
3,212,871
– –
MMSI icon
18
Merit Medical Systems
MMSI
$5.15B
$55.4M 1.45%
1,082,013
+37,000
+4% +$1.83M
QURE icon
19
uniQure
QURE
$2.99B
$54.6M 1.43%
1,444,628
+50,000
+4% +$1.6M
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$54.1M 1.42%
1,089,169
+254,490
+30% +$12.3M
MGTX icon
21
MeiraGTx Holdings
MGTX
$1.23B
$53.9M 1.41%
+4,703,398
New +$63.1M
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
$52.5M 1.38%
13,165,746
+8,000,000
+155% +$31.2M
QTNT
23
DELISTED
Quotient Limited Ordinary Shares
QTNT
$52.1M 1.36%
162,076
+11,250
+7% +$2.63M
CORI
24
DELISTED
Corium International, Inc.
CORI
$50.9M 1.34%
6,357,133
– –
ISRG icon
25
Intuitive Surgical
ISRG
$133B
$47.8M 1.25%
300,000
+270,000
+900% +$41.2M
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Perceptive Advisors held 160 positions worth $3.81B, up 6.8% from $3.57B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2018 filing shows 23 new, 21 increased, 32 reduced and 35 closed positions. Its largest new stake was Verrica Pharmaceuticals: 341,041 shares worth $67.3M. The largest sale was Abiomed Inc, an estimated $107M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Industrials.

  • Perceptive Advisors's largest Q2 2018 buy was Verrica Pharmaceuticals: 341,041 shares worth $67.3M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2018, an estimated $56.2M increase.
  • Perceptive Advisors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $107M.
  • Perceptive Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $34.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.81B portfolio in Q2 2018.
  • Perceptive Advisors opened 23 new positions and closed 35 in Q2 2018.
  • Perceptive Advisors's portfolio value rose 6.8% quarter-over-quarter to $3.81B.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.